Novel Augmentation of DAOIB and Antioxidant for Early Dementia
Recruiting · NCT06467539 · Interventional (participants receive a specific treatment) · Lead sponsor: Chang Gung Memorial Hospital
View the official record on ClinicalTrials.gov →Interventions studied
DAOIB plus AODAOIB plus placebo
What this trial is about
Previous studies found that some NMDA-enhancing agents were able to improve cognitive function of patients with early-phase dementia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of dementia too. Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than an NMDA-enhancing agent alone deserves study.
Who can take part
Age range
50 Years to 90 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Clinical diagnosis of Alzheimer's disease or mild cognitive impairment
- MMSE between 10-26
- CDR 1 or 0.5
Exclusion criteria
- Hachinski Ischemic Score \> 4
- Substance abuse/dependence
- Parkinson disease, epilepsy, dementia with psychotic features
- Major depressive disorder
- Major physical illnesses
- Severe visual or hearing impairment
Where it is running
1 location listed.
- Chang Gung Memorial Hospital - Kaohsiung City, Taiwan